 NEW YORK, Nov. 04, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, announced the release of two abstracts at the American Society of Hematology ASH Annual Meeting, one oral presentation of initial data for its BALLI-01 clinical trial and one Trials in Progress poster presentation of its AMELI-01 clinical trial. This will be the first publicly released data from Cellectis Phase 1 dose-escalation study of UCART22 product candidate in adult patients with RelapsedRefractory CD22 B-ALL. 